FDA approves Tecartus for B-cell precursor acute lymphoblastic leukemia – Kite
Kite announced the FDA has granted approval for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute… read more.